Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd (KMDA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products for rare and serious conditions. Its news flow reflects activity across commercial operations, clinical programs, plasma collection, and corporate strategy.
On this page, readers can follow Kamada news related to its proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Company announcements frequently discuss revenue trends, adjusted EBITDA, and guidance, highlighting the contribution of its Proprietary Products and Distribution segments, including biosimilar launches in Israel and supply agreements in markets such as Canada.
News items also cover clinical and post-marketing research, including updates on the InnovAATe Phase 3 trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency and its subsequent discontinuation following an interim futility analysis, as well as the SHIELD study evaluating CYTOGAM in high-risk kidney transplant recipients. Regulatory and operational milestones, such as FDA approval of the Houston, Texas plasma collection center and expansion of plasma collection capacity across Kamada’s three Texas sites, are recurring topics.
Investors and followers of KMDA stock can use this feed to track quarterly and annual financial results, guidance updates, tender awards like the Canadian Blood Services supply extension, and participation in healthcare and investor conferences. Regularly reviewing this page provides a consolidated view of Kamada’s commercial progress, R&D developments, and strategic initiatives as reported in its press releases and related filings.
Kamada Ltd. (NASDAQ: KMDA), a biopharmaceutical company focusing on rare diseases, will announce its financial results for Q4 and the full year ending December 31, 2022, on March 15, 2023, before U.S. market open. A conference call will be held the same day at 8:30 AM ET to discuss the results. Investors can participate by calling specific numbers or via a live webcast. Kamada's portfolio includes six FDA-approved plasma-derived products and a notable investigational product for AAT deficiency currently in a pivotal Phase 3 trial. The company aims to drive growth through its commercial strategies and R&D advancements.
Kamada Ltd. (NASDAQ: KMDA) announced it has submitted an application to the FDA to manufacture CYTOGAM® at its Israeli facility, expecting approval by mid-2023. This marks the completion of the technology transfer from CSL Behring. CYTOGAM is crucial for preventing cytomegalovirus disease post-transplantation and has the highest sales among Kamada's acquired IgG products, with gross margins exceeding 50%. The company plans to initiate commercial manufacturing in the second half of 2023, leveraging its operational capabilities for increased efficiency.
Kamada Ltd. (NASDAQ: KMDA) announced that its CFO, Chaime Orlev, will leave the company effective March 15, 2023, to pursue new opportunities. Orlev has been with Kamada since 2017 and played a crucial role in its transformation into a diversified biopharmaceutical company. As part of the transition, he will support the onboarding of his successor. Kamada specializes in specialty plasma-derived therapeutics and has a robust portfolio of FDA-approved products. It operates in over 30 countries and continues to advance its development pipeline, including ongoing clinical trials.
Kamada Ltd. (NASDAQ: KMDA) reported third-quarter 2022 revenues of $32.2 million, a 40% increase from the previous year, driven by the integration of its new FDA-approved IgG portfolio. Adjusted EBITDA reached $6.0 million, equating to a 19% margin. The company’s operating cash flow amounted to $5.5 million, elevating its cash position to $31.3 million as of September 30, 2022. Kamada reiterates its fiscal year 2022 revenue guidance of $125 million to $135 million, projecting a 20% to 30% increase over 2021.
Kamada Ltd. (NASDAQ: KMDA) is set to release its financial results for Q3 and the first nine months of 2022 on November 22, 2022, before U.S. markets open. Following the announcement, management will host a conference call at 8:30 AM ET to discuss the results. Investors can participate by phone or by joining a live webcast. Kamada specializes in plasma-derived therapeutics and has a diverse product portfolio including GLASSIA® and KEDRAB®. The company is focused on profitable growth and has a strong presence in the bio-pharmaceutical market.
Kamada Ltd. (NASDAQ: KMDA) announced progress in its pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy aimed at treating Alpha-1 Antitrypsin Deficiency (AATD). With 30 patients enrolled, the trial has proceeded without modification for the fourth time, according to the Data Safety Monitoring Board. Importantly, inclusion criteria were revised to enroll patients with severe airflow limitation, enhancing recruitment potential. The company plans to meet with the FDA and EMA in H1 2023 to discuss study progress and regulatory pathways.
Kamada Ltd. (NASDAQ: KMDA), a global biopharmaceutical company specializing in plasma-derived therapeutics, announced that Amir London, CEO, will present at the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 3:50 p.m. ET. Additionally, Mr. London will be available for virtual one-on-one investor meetings during the event. Interested investors should contact their Credit Suisse representative. The presentation will be accessible via a live webcast on Kamada's investor relations page, with a replay available for 30 days.
Kamada Ltd. (NASDAQ: KMDA) announced an extension of its supply tender with Canadian Blood Services for four specialty IgG products, securing about $7.5 million per year from 2023-2025, totaling approximately $22 million. The products, acquired in 2021, include CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF. The deal reinforces Kamada’s position in the Canadian market and follows a recent $11.4 million agreement for VARIZIG in Latin America. Manufacturing of CYTOGAM is set to begin in 2023 at Kamada's Israeli facility, pending regulatory approvals.
Kamada Ltd. (NASDAQ: KMDA) reported second quarter 2022 revenues of $23.6 million, down 3% from $24.2 million year-over-year, while first half revenues rose 5% to $51.7 million. Adjusted EBITDA for H1 2022 was $4.6 million, with a cash flow increase to $29.9 million. The company is optimistic about a stronger second half, reiterating fiscal year revenue guidance of $125-$135 million, reflecting 20%-30% growth. Challenges include a $3.3 million loss due to a labor strike and increased operating expenses. The firm anticipates growth from new IgG products and royalty income from GLASSIA.
Kamada Ltd. (NASDAQ: KMDA) will release its Q2 and first-half financial results on August 17, 2022, before U.S. market open. An investment community conference call will follow at 8:30 AM ET, with participation options provided. The company focuses on specialty plasma-derived therapeutics, boasting a diverse portfolio including FDA-approved products such as GLASSIA® and KEDRAB®. Kamada also has a robust development pipeline, particularly in inhaled AAT therapy for AAT deficiency, currently in a pivotal Phase 3 trial.